title: Statement of the AGNP in the Context of the Planned Formation of a Fixed Reference Price Group "GABA-Analogues", November 21, 2011.
authors.affiliation: Department of Psychiatry, Max Planck Institute of Psychiatry, Kraepelinstrasse 2, 080804 Munich, Germany. s teiger@mpipsykl.mpg.de
authors.forename: A
authors.initials: A
authors.lastname: Steiger
mesh_terms: D000588:Amines / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D000077206:Gabapentin; D005858:Germany; D006801:Humans; D019458:Insurance Coverage / Q000191:economics / Q000331:legislation & jurisprudence; D007349:Insurance, Health, Reimbursement / Q000191:economics* / Q000331:legislation & jurisprudence*; D000069583:Pregabalin; D012958:Societies, Scientific; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000588:Amines; D014151:Anti-Anxiety Agents; D003509:Cyclohexanecarboxylic Acids; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin